Dublin, Jan. 12, 2026 (GLOBE NEWSWIRE) — The “Peptide Therapeutics Market: Industry Trends and Global Forecasts, Till 2040 – Distribution by Type of Peptide, Route of Administration, Key Therapeutic Area and Geographical Regions” has been added to ResearchAndMarkets.com’s offering.
The peptide therapeutics market is projected to expand from USD 84.2 billion to USD 162.4 billion by 2035, registering a CAGR of 6.8% during this period. Peptide therapeutics, developed from polypeptides, address various illnesses and include treatments for metabolic diseases, cancer, and hormonal disorders.
Driven by increasing occurrences of chronic conditions like diabetes, cancer, and autoimmune disorders, the demand for peptide therapies has surged. FDA-approved peptide therapeutics, such as Tirzepatide (Mounjaro) and Lutetium Lu-177 vipivotide tetraxetan (Pluvicto), highlight the market’s growth potential. Pharmaceutical companies are focusing on innovative drug conjugates to tackle a broad spectrum of diseases.
The report outlines critical insights into the peptide therapeutics market’s current state and future opportunities:
- Boasting over 25 approved drugs and 280 candidates in development, peptide therapeutics represent a rapidly expanding drug class.
- The development pipeline features peptides being tested for various delivery routes, primarily targeting metabolic and oncological disorders.
- Global clinical trials, numbering over 1,200, emphasize the focus on metabolic disease treatment.
- An increasing number of partnerships, predominantly in technology and product licensing, underscores the sector’s momentum.
- Investments exceeding USD 7 billion from public and private sectors reflect burgeoning interest and potential returns.
The peptide therapeutics market is segmented into key areas:
- Medium Size Peptides: Medium-sized peptides dominate with a substantial share, attributed to their effective balance in size. Small peptides are projected to grow at over 20% CAGR, owing to their application in targeted drug manufacturing.
- Subcutaneous Route of Administration: The subcutaneous route holds a majority share due to its ability to bypass first-pass metabolism, enhancing therapeutic effectiveness. Demand for non-invasive routes suggests significant growth potential in topical administration.
- Metabolic Diseases: This segment is prime, driven by the pronounced need for treatments addressing diabetes and obesity. The market share for gastrointestinal disease peptides is set to expand significantly, with a 25% CAGR anticipated.
- Geographical Insights: North America leads in market share, with chronic disease prevalence propelling demand. The Asia-Pacific market is expected to grow at a higher CAGR during the forecast period.
Prominent players in the peptide therapeutics market include Apellis Pharmaceuticals, BioLineRx, Eli Lilly, Novo Nordisk, Takeda, and Zealand Pharma.
Key research areas explored in the report encompass market sizing, pipeline analysis, company profiles, and big pharma initiatives. The report addresses numerous critical questions and provides robust data supporting strategic decisions.
Purchase this report to harness detailed market analyses, understand competitive dynamics, and leverage insights for future growth. Additional benefits include Analytics Packs, free content customization, and report walkthrough sessions with the research team.
Key Attributes
| Report Attribute | Details |
| No. of Pages | 250 |
| Forecast Period | 2025-2035 |
| Estimated Market Value (USD) in 2025 | $84.2 Billion |
| Forecasted Market Value (USD) by 2035 | $162.4 Billion |
| Compound Annual Growth Rate | 6.8% |
| Regions Covered | Global |
A selection of companies mentioned in this report includes, but is not limited to:
- 13therapeutics
- 7 Med Health Ventures
- 9 Meters Biopharma
- Abbott
- Abingworth
- Acorn Bioventures
- ACT Capital Management
- Adage Capital Management
- Adams Street Partners
- Advanced Accelerator Applications
- Aileron Therapeutics
- AJU IB Investment
- Akashi Therapeutics
- Alexion Pharmaceuticals
- Allysta Pharmaceuticals
- Alphabet venture arm
- Altimmune
- Amgen
- Amolyt Pharma
- Ampio Pharmaceuticals
- Amyndas Pharmaceuticals
- Andera Partners
- Angiochem
- Anji Pharmaceuticals
- AOP Orphan Pharmaceuticals
- Apellis Pharmaceuticals
- Apeptico
- APIM Therapeutics
- Apitope
- Aquestive Therapeutics
- Arch Biopartners
- ARCH Venture Partners
- Arix Bioscience
- Asahi Kasei
- AsclepiX Therapeutics
- Astellas Pharma
- AstraZeneca
- Atlas Venture
- Atox Bio
- Aurinia Pharmaceuticals
- Avilex Pharma
- Avion Pharmaceuticals
- Barer & Son Capital
- Bayer
- Becker
- Belfius
- Bergens forskningsstiftelse
- Beth Israel Deaconess Medical Center
- Better Ventures
- Bicycle Therapeutics
- Biogenosis
- Bioglan
- BioLineRx
- Biolingus
- Biomarck Pharmaceuticals
- BioMarin Pharmaceutical
- Biomedical Advanced Research and Development Authority (BARDA)
- BiomedInvest
- BioMedPartners
- Bios Partners
- Biosciences Research & Commercialization Center
- BioSkin
- BL&H
- Boehringer Ingelheim
- Boehringer Ingelheim Venture Fund
- Boryung Pharmaceutical
- Bossa Ventures
- Boston Therapeutics
- Bpifrance
- Brightlands Life Sciences Ventures
- Bristol Myers Squibb
- Buttonwood
- BVF Partners
- Cambridge Innovation Capital (CIC)
- Canaccord Genuity
- CanBas
- Cancer Research UK
- Capital Community Angels
- Cara Therapeutics
- CARB-X (Combating Antibiotic Resistant Bacteria Biopharmaceutical Accelerator)
- Cardiorentis
- Carmot Therapeutics
- Catalent
- Cathay Venture
- Celgene
- Cellastra
- Cend Therapeutics
- Chiasma Pharma
- Chondropeptix
- Chrysalis BioTherapeutics
- Clinical Research Center for Hair and Skin
- Clinuvel Pharmaceuticals
- CohBar
- Cold Spring Harbor Laboratory
- Constant Therapeutics
- Contura
- Cormorant Asset Management
- CureDM
- Curonz
- Cutanea Life Sciences
- Cystic Fibrosis Foundation Therapeutics
- Cytovation
- Dana-Farber/Boston Children’s Cancer and Blood Disorders Center
- Deerfield Management
- Diabetology
- Diapin Therapeutics
- E&Investment
- Eczacibasi
- Elan Pharmaceuticals
- Eli Lilly
- Endo Ventures
- Entera Bio
- Enteris BioPharma
- Epidarex Capital
- Epimede
- Eshelman Ventures
- Esperance Pharmaceuticals
- European Commission
- F2 Capital
- F4 Pharma
- Fannin Partners
- Ferring Pharmaceuticals
- First In Ventures
- FirstString Research
- Follicum
- Foresite Capital
- Founders Fund
- Fountain Healthcare Partners
- F-Prime Capital Partners
- Frontier Biotechnologies
- FUJIFILM Toyama Chemical
- Genentech
- Genervon Biopharmaceuticals
- GeneScience
- Genus Oncology
- GF Ventures
- Gila Therapeutics
- GlaxoSmithKline
- GlioCure
- GlycoNet
- Google Ventures
- Government of Canada
- Government of Quebec
- Grand Oaks Capital
- G-tree BNT
- GYRUS Pharma
- HBG Beteiligungs- und Beratungsgesellschaft
- HealthCare Royalty Partners (HCR)
- Healthlink Capital
- Hercules Capital
- Hestia Investments
- HighTide Therapeutics
- Hillhouse Capital Group
- Horizon Technology Finance
- Horizons Ventures
- iBio
- ILC Therapeutics
- Imcyse
- ImmuPharma
- InCube Ventures
- InFocus Capital Partners
- InnoBio 2
- Innovate UK
- Inotrem
- Integra Holdings
- Inter-American Development Bank (IDB)
- InterK Peptide Therapeutics
- Intervest
- Invest Michigan
- Investinor
- Invus
- Ipsen
- Issar Pharmaceuticals
- Janssen Biotech
- Janssen Pharmaceuticals
- JDRF
- Jennison Associates
- Johnson & Johnson
- Kairos Ventures
- Kaitai Capital
- Kalos Therapeutics
- KeyBioscience
- Knoll Capital Management
- KPC Pharmaceuticals
- Kreos Capital
- KU Leuven
- Kurma Partners
- L1 Capital Global Opportunities Master Fund
- La Jolla Pharmaceutical
- Lanstead Capital
- Lassogen
- Lincoln Park Capital Fund
- Lind Global Macro Fund
- LipimetiX Development
- Live Like Bella Foundation
- Longevity Biotech
- Longwood Fund
- Lonza
- LRM Funds
- LSP
- Lundbeckfonden Ventures
- Madryn Asset Management
- Maven Investment Partners
- Maxim Group
- MEDARVA Foundation
- MedImmune
- Mediolanum Farmaceutici
- Megapharm
- MElkin Pharmaceuticals
- Merck
- Merck Sharp & Dohme (MSD)
- MeSCue-Janusys
- Michigan Capital Network Venture Fund III
- Mitsubishi Tanabe Pharma
- Morningside Ventures
- MPM Capital
- Nan Fung Technology’s Pivotal Beta
- Nanomerics
- National Cancer Institute (NCI)
- National Eye Institute (NEI)
- National Heart, Lung, and Blood Institute (NHLBI)
- National Institute of Allergy and Infectious Diseases
- National Institute of Dental and Craniofacial Research (NIDCR)
- National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)
- National Institutes of Health (NIH)
- National Multiple Sclerosis Society
- National Research Council Canada
- Neuro-Bio
- NeuroRx
- New Enterprise Associates
- NextPharma
- NoNO
- Noshaq
- NovaCell Technology
- Novartis
- Novartis Venture Fund
- Novo Nordisk
- Novo Ventures
- NV Industriebank LIOF
- Oncology Pharma
- Oncopeptides
- ONL Therapeutics
- Onyx Therapeutics
- OPKO Health
- Oramed Pharmaceuticals
- OrbiMed
- Otsuka Pharmaceutical
- Ovoca Bio
- Oxalo Therapeutics
- Oxurion
- PAION
- Palatin Technologies
- Park West Asset Management
- Partners Innovation Fund
- PEP-Therapy
- PeptiDream
- Peptilogics
- Peptron
- Perceptive Xontogeny Venture Fund
- Pfizer
- Pfizer Venture Investments
- Pharma Research Products
- PharmaMar
- Pharmstandard International
- Piedmont Capital Partners
- PIN Pharma
- Ping An Ventures
- Pint Pharma
- Playground Global
- PMV
- Polyphor
- Pontifax
- Praxis Pharmaceutical
- Presight Capital
- Priavoid
- proDERM
- ProLynx
- ProMore Pharma
- ProNeurogen
- Protagonist Therapeutics
- Protagenic Therapeutics
- Proteimax
- PSQ Capital
- Pulmotect
- Qilu Pharmaceutical
- Quaker Partners
- Quantum Leap Healthcare Collaborative (QLHC)
- Quartesian
- Radius Health
- Rani Therapeutics
- Rapha Capital Management
- RegeneRx Biopharmaceuticals
- ReGenTree
- ReumaNederland
- Rhythm Pharmaceuticals
- Riesner Verwaltungs
- Roche
- Rock Springs Capital Management
- Salem Partners
- Salix Pharmaceuticals
- Sanofi
- Sanofi-Aventis
- Santhera Pharmaceuticals
- Sapience Therapeutics
- Sarsia Seed
- Satter Medical Technology Partners
- SciClone Pharmaceuticals
- Scios (Acquired by Johnson & Johnson)
- Seachaid Pharmaceuticals
- Sectoral Asset Management
- Serpin Pharma
- Seventure Partners
- SFJ Pharmaceuticals
- Shanghai Fosun Pharmaceutical
- Shire
- SIRS Therapeutics
- Societe Federale de Participations et d’Investissement (SFPI)
- Societe Regionale d’Investissement de Wallonie (SRIW)
- Sofinnova Ventures
- Soligenix
- Sophos Capital
- Soricimed Biopharma
- Specialised Therapeutics
- SR One
- Stealth BioTherapeutics
- SV Health Investors
- Swedish Orphan Biovitrum (SOBI)
- SYNG Pharmaceuticals
- TaiAn Technologies
- Takeda
- Tarsa Therapeutics
- TearSolutions
- Technomark Life Sciences
- TEDCO
- Televenture (Funded through NIK III)
- Texas A&M University Health Science Center
- The Column Group
- The Leona M. and Harry B. Helmsley Charitable Trust
- University of Bath
- The University of Chicago Innovation Fund
- The University of Texas MD Anderson Cancer Center
- TheraSource
- Theratechnologies
- Third Rock Ventures
- Topas Therapeutics
- Tsingyuan Ventures
- TTY Biopharm
- TwoToBiotech
- UCB Pharma
- University of Freiburg
- University of Missouri Research Reactor (MURR)
- University of St Andrews
- US Department of Defense
- UVA Seed Fund
- ValiRx
- Vault Pharma
- Vaxeal
- venBio Global Strategic Fund
- Ventac Partners
- VentureHealth
- Vertex Ventures
- Vesalius Biocapital
- Viatem
- Vifor Pharma
- Vinnova
- Virtus Inspire Ventures
- Vivo Capital
- VTC Innovation Fund
- Wales Life Sciences Fund
- West Midlands Academic Health Science Network (WMAHSN)
- WuXi AppTec
- Wyvern
- Xigen
- YuYang D&U
- Zealand Pharma
- Zucara Therapeutics
For more information about this report visit https://www.researchandmarkets.com/r/qwndtg
About ResearchAndMarkets.com
ResearchAndMarkets.com is the world’s leading source for international market research reports and market data. We provide you with the latest data on international and regional markets, key industries, the top companies, new products and the latest trends.
- Peptide Therapeutics Market
